Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10502 + nab-paclitaxel or docetaxel or irinotecan
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
HS-10502 is an orally bioavailable, selective inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), developed by Jiangsu Hansoh Pharmaceutical. It blocks PARP1 activity, thereby preventing DNA repair via the base excision repair pathway and exerting antineoplastic effects[1][3][4]. In clinical studies, it is being evaluated in combination with other chemotherapeutic agents—including nab-paclitaxel (albumin-bound paclitaxel), docetaxel, or irinotecan—for advanced solid tumors such as recurrent ovarian cancer, HER2-negative advanced breast cancer, triple-negative breast cancer (TNBC), advanced prostate cancer, and advanced gastric cancer[5][7]. Nab-paclitaxel works by inhibiting cell division through microtubule stabilization; docetaxel also stabilizes microtubules to prevent cell division; irinotecan inhibits topoisomerase I to block DNA replication[6][8].
- Brand names
- Abraxane (nab-paclitaxel)Taxotere (docetaxel)
- Other names
- HS 10502HS10502HS-10502
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on HS-10502 + nab-paclitaxel or docetaxel or irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10502 + nab-paclitaxel or docetaxel or irinotecan.